News Features Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile Michael O'Riordan October 17, 2025
News Daily News CVD Still the Leading Cause of Death and Disease Globally Michael O'Riordan September 24, 2025
News Conference News ESC 2025 PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy Michael O'Riordan September 01, 2025
News Daily News Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM L.A. McKeown April 15, 2025
News Daily News Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More Michael O'Riordan December 06, 2024
News Conference News HFSA 2024 ‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM L.A. McKeown October 02, 2024
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News HRS 2024 Goal of Arrhythmia Care in Athletes is a Return to Play: HRS Consensus Michael O'Riordan May 23, 2024
News Conference News ESC Heart Failure 2024 SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM Michael O'Riordan May 13, 2024
News Conference News ACC 2024 IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM Caitlin E. Cox April 15, 2024
News Conference News ESC Heart Failure 2023 Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues Shelley Wood May 25, 2023
News Features Heart Failure Care Has a Pipeline Problem: What’s the Fix? Shelley Wood December 20, 2022
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Daily News Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM Todd Neale September 15, 2022
News Daily News Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive Michael O'Riordan September 09, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report Michael O'Riordan January 27, 2022